Category - Markets

William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday. After markets closed on Nov. 29...

Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday. Analyst Seamus Fernandez writes that the company’s lead asset, A...

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with...

Piper Jaffray initiated coverage of Bovie Medical (NYSE:BVX) with an “overweight” rating and $6 price target. The stock closed at $4.24 on Friday. Bovie is best known within the operating room for its electrocautery...

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday. Analyst Andre Uddin writes that...

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday. In a new report, analyst Matthew Kaplan writes that Repros...

Canaccord Genuity and BTIG initiated coverage of iRhythm Technologies (NASDAQ:IRTC) with “buy” ratings and price targets of $31 and $28, respectively. The stock closed at $24.23 on Friday. iRhythm is a digital health...

Leerink resumed coverage of T2 Biosystems (NASDAQ:TTOO) with a “market perform” rating and $5 price target. The stock finished at $6.31 on Wednesday. “While we view T2’s proprietary T2MR pathogen detection technology...

Leerink resumed coverage of Invitae (NASDAQ:NVTA) with an “outperform” rating and $12 price target. The stock closed at $8.44 on Wednesday. Analyst Puneet Souda writes that Invitae is a high growth, commercial-stage...

Roth Capital Partners upgraded Applied Genetic Technologies (NASDAQ:AGTC) to “buy” from “neutral” and raised its price target to $15 from $12. The stock jumped $2.15 to $9.20 in afternoon trading on Wednesday. “With...